Wells Fargo & Company Entrada Therapeutics, Inc. Transaction History
Wells Fargo & Company
- $407 Billion
- Q2 2024
A detailed history of Wells Fargo & Company transactions in Entrada Therapeutics, Inc. stock. As of the latest transaction made, Wells Fargo & Company holds 10,899 shares of TRDA stock, worth $209,587. This represents 0.0% of its overall portfolio holdings.
Number of Shares
10,899
Previous 7,597
43.46%
Holding current value
$209,587
Previous $107,000
44.86%
% of portfolio
0.0%
Previous 0.0%
Shares
11 transactions
Others Institutions Holding TRDA
# of Institutions
88Shares Held
27.9MCall Options Held
100Put Options Held
0-
Baker Bros. Advisors LP New York, NY4.87MShares$93.6 Million0.92% of portfolio
-
Mpm Asset Management LLC Cambridge, MA4.43MShares$85.1 Million34.63% of portfolio
-
5 Am Venture Management, LLC San Francisco, CA4.41MShares$84.8 Million29.39% of portfolio
-
Price T Rowe Associates Inc Baltimore, MD3.13MShares$60.3 Million0.01% of portfolio
-
Black Rock Inc. New York, NY1.69MShares$32.6 Million0.0% of portfolio
About Entrada Therapeutics, Inc.
- Ticker TRDA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 31,368,500
- Market Cap $603M
- Description
- Entrada Therapeutics, Inc., a biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its endosomal escape vehicle platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. The company's lead product candidate is ENTR-601-44, which is in precli...